Kezar Q1 net loss narrows to $5.8 million; operating loss narrows to $7.4 million

KEZAR LIFE SCIENCES, INC.

KEZAR LIFE SCIENCES, INC.

KZR

0.00
  • Kezar Life Sciences posted a net loss of USD 5.8 million for the quarter ended March 31, 2026, narrowing from USD 16.6 million a year earlier.
  • Operating loss narrowed to USD 7.4 million from USD 17.7 million, with total operating expenses dropping to USD 7.4 million from USD 17.7 million.
  • Research and development expense fell to USD 1.5 million from USD 12.2 million, while general and administrative expense edged down to USD 5.2 million from USD 5.5 million.
  • Interest income slipped to USD 0.6 million from USD 1.4 million, while the quarter included a USD 1 million gain on sale of a nonfinancial asset.
  • Kezar entered a merger agreement with Aurinia Pharma U.S. on March 30, 2026, with an offer price of USD 6.955 per share in cash plus one contingent value right; the tender offer began April 13, 2026 and can be terminated if not consummated by June 28, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kezar Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-033104), on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.